NCT02882451 is a NA clinical trial of pinaverium bromide in Bile Duct Diseases, sponsored by Changhai Hospital.

Who is sponsoring NCT02882451?

NCT02882451 is sponsored by Changhai Hospital.

What drugs are being tested in NCT02882451?

Interventions in NCT02882451: pinaverium bromide, Vitamin C.

What condition does NCT02882451 study?

NCT02882451 studies Bile Duct Diseases.

Is NCT02882451 still recruiting?

NCT02882451 is currently status unknown. Last updated 9 June 2017.

Last reviewed 2017-06-09 · How we verify

NCT02882451

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Pinaverium Bromide on Bile Duct and Pancreatic Duct Cannulation During Endoscopic Retrograde Cholangiopancreatography

Status unknown NA Last updated 9 June 2017

What this trial tests

NA trial testing pinaverium bromide in Bile Duct Diseases in 200 participants. Status unknown.

Timeline

1 July 2016

Primary endpoint
1 August 2017

1 October 2017

Quick facts

Lead sponsor	Changhai Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	200
Start date	1 July 2016
Primary completion	1 August 2017
Estimated completion	1 October 2017
Sites	1 location across China

Drugs / interventions tested

pinaverium bromide — full drug profile →
Vitamin C — full drug profile →

Conditions studied

Bile Duct Diseases — all drugs for Bile Duct Diseases →

Sponsor

Changhai Hospital

Who can join

Adults 18 to 80, any sex, with Bile Duct Diseases. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

cannulation time for deep bile duct cannulation and pancreatic duct cannulation
Time frame: 2 days

Sponsor's own description

Pinaverium bromide can be used to treat symptoms related to irritable bowel syndrome (IBS) and functional disorders of the biliary tract. In this study, pinaverium bromide was compared with Vitamin C for the facilitation of bile duct and pancreatic duct cannulation in patients. The primary outcome was successful deep bile duct cannulation and pancreatic duct canulation. The second outcome was the major papillary orifice,bile juice flow from the papilla, time to achieve deep bile duct cannulation, fluoroscopy time for deep bile duct cannulation,the appearance of the major and minor papillary orifice, pancreatic juice flow from the papilla, time to achieve deep pancreatic duct cannulation, and fluoroscopy time for deep pancreatic duct cannulation in the pinaverium bromide group versus Vitamin C group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Bile Duct Diseases

Currently open trials in the same condition.

NCT07263061 — Time to Post-operative Recovery of Serum Albumin as a Predictor of Outcome in Major Hepato Pancreato Biliary Surgeries · recruiting
NCT06010576 — Endoscopic Ultrasound-guided Rendezvous Versus Precut Papillotomy · NA · recruiting
NCT05689255 — Gut Microbiome and Metabolome in Patients With Gallstone Disease After Surgical and Endoscopic Interventions · recruiting
NCT05014347 — Patient Reported Experience in Endoscopic Ultrasound · active not recruiting

Other Changhai Hospital trials

Trials by the same sponsor.

NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02882451 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
Last refreshed: 9 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02882451.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing